Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q1 2024 · 10-Q
Revenue$17.58M$17.58M+100.3% vs Q1 2023 Net Income$8.59M$8.59MN/M vs Q1 2023 EPS Diluted$1.70$1.70N/M vs Q1 2023 Operating Income-$4,187,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
Free Cash Flowderived-$19,067,000N/M Margins · derivedOperating margin-23.8%+128.3 pt vs Q1 2023
Net margin48.8%+334.3 pt vs Q1 2023
ended Mar 31, 2024 · filed May 13, 2024 · 43 d after period end